Iyul: 2022: On July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing a next-generation chimeric antigen receptor (CAR)-T cell therapy platform targeting solid cancer, announced that they had entered into a strategic partnership MOU concerning the development of a new CAR-T cell therapies. The MOU was in regard to the development of new CAR-T cell therapies. Through the use of this memorandum of understanding (MOU), GenScript ProBio and ACT Therapeutics have come to an agreement to further their collaboration in the field of cell therapy.
ACT Therapeutics va GenScript ProBio kompaniyalari ACT Therapeutics’ning Advanced CAR-T Platformasining (ACT platformasi) birinchi quvur liniyasi uchun plazmid va virus vektorlarini ishlab chiqish va ishlab chiqarish bo‘yicha shartnoma imzolash jarayonida, u ham xom ashyo ishlab chiqarishga topshiriladi. ACT Therapeutics kompaniyasining keyingi quvurlari uchun. Shartnoma ACT Therapeutics kompaniyasining Advanced CAR-T Platformasining birinchi quvur liniyasi uchun plazmidlar va virus vektorlarini ishlab chiqarishni qamrab oladi.
Ushbu kelishuv natijasida GenScript ProBio ACT terapevtikalari uchun ACT platformalarini qo'llab-quvvatlay oladigan global hamkor maqomiga ko'tarildi.
ACT platformasi yangi avlod hujayra va gen terapiyasi texnologiyasi bo'lib, u antijenlarni immun hujayralarga maqsad qilib qo'yish uchun mo'ljallangan genlarni kiritish orqali saraton antijenlarini nishonga oladi. Ushbu genlar virus vektorlari yordamida immunitet hujayralariga etkaziladi. GenScript ProBio yuqori sifatli virus vektor jarayonini ishlab chiqish va GMP ishlab chiqarish uchun bir martalik xizmat ko'rsatish platformasiga ega, ularning ikkalasi ham hujayra va gen terapiyasini rivojlantirish uchun zarurdir.
ACT Therapeutics’ ACT platform is an advanced CAR-T technology that has a next-generation structure that goes beyond the second-generation CAR-T cell therapy and targets existing qon saratoni. This is accomplished by overcoming the immune suppression microenvironment of solid cancer and activating the immune cells that are surrounding the cancer. Several studies have also used animals to test the ACT platform to see how well it works and if it is safe. These studies have also confirmed that the platform can be used to treat solid cancer while staying in the immunosuppressive environment of that cancer. Additionally, it complements the shortcomings of the existing second-generation CAR-T, which makes it a competitive technology for the treatment of solid cancer.
ACT Therapeutics is a Korean bio venture company that has received initial investment through DAYLI Partners, Korea’s leading bio and healthcare venture capital, since its establishment in 2020, and has been recognized for its technology such as receiving pre-series A investment in Samho Green Investment. DAYLI Partners is Korea’s leading bio and healthcare venture capital since its establishment in 2020. At the moment, investment consultations are being held with various securities firms and venture capital companies in order to entice Series A investment.
Brian H. Min, CEO of GenScript ProBio, said, “We are very happy to cooperate with ACT therapeutics in strategic partnership, and we are looking forward to support ACT Therapeutics’ ACT platform as a global partner through our accumulated technology.”
Seogkyoung-Kong, ACT Therapeutics bosh direktori, “Biz GenScript ProBio bilan strategik hamkorlik orqali ACT platformasining global miqyosda paydo bo'lishiga tayyorgarlikni yakunladik. Biz o'tga chidamli va davolab bo'lmaydigan qattiq saratonga qaratilgan davolash usullarini ishlab chiqishni tezlashtiramiz.
GenScript ProBio haqida
GenScript ProBio is a subsidiary of GenScript Biotech Corporation, proactively providing end-to-end CDMO service from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in cell and gene therapy (CGT), vaccine discovery, biologics discovery and antibody protein drug development to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, Shanghai, Hong Kong, Nanjing and other places to serve global customers, and supported customers in the United States, Europe, Asia Pacific and other regions to obtain more than 30 IND approvals.
GenScript ProBio “Hamkorlik orqali innovatsiyalar” missiyasi yo‘lida mijozlarga biologik preparatlarni ishlab chiqish vaqtini kashf qilishdan tortib to tijoratlashtirishgacha qisqartirishga, ilmiy-tadqiqot va ishlanmalar xarajatlarini sezilarli darajada kamaytirishga va sog‘lom kelajakni qurishga yordam berishga intiladi.
